Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 5:00 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 2,507 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Sequence Clear all
Completed Phase 1 Interventional

A Study to Assess the Effect of Danicamtiv on the Drug Levels of Midazolam in Participants With Stable Heart Failure

NCT05952089
View directory record Official record
Conditions
Heart Failure With Reduced Ejection Fraction
Interventions
Danicamtiv, Midazolam
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 75 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
5
States / cities
Fort Lauderdale, Florida • Inverness, Florida • Jacksonville, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2024 · Synced Nov 1, 2026, 5:00 PM EST
Recruiting Phase 2 Interventional

Magnetic Resonance (MR) Imaging With Hyperpolarized 13C-Pyruvate +/- 13C,15N-Urea in Patients With Prostate Cancer

NCT06391034
View directory record Official record
Conditions
Prostate Cancer
Interventions
hyperpolarized pyruvate +/-urea (13C/15N), Non-investigational External beam radiotherapy (EBRT), Radiotherapy (RT), Multi-parametric magnetic resonance imaging (mpMRI), Non-interventional hormone therapy, Prostate Biopsy
Drug · Radiation · Procedure + 1 more
Lead sponsor
Robert Bok, MD, PhD
Other
Eligibility
18 Years and older · Male only
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Nov 1, 2026, 5:00 PM EST
Completed Phase 3 Interventional

A Study to Investigate the Effect on Lung Function of an Approved COPD Treatment (BGF, With HFA Propellant) Compared to BGF Formulated With a Next-Generation Propellant in Participants 40 to 80 Years of Age With COPD

NCT06075095
View directory record Official record
Conditions
COPD (Chronic Obstructive Pulmonary Disease)
Interventions
BGF MDI HFO 320/14.4/9.6μg, BGF MDI HFA 320/14.4/9.6 μg, Placebo MDI HFA
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 80 Years
Enrollment
297 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
19
States / cities
Sheffield, Alabama • Clearwater, Florida • Gainesville, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2025 · Synced Nov 1, 2026, 5:00 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1A Study of the Safety of KSP/QRH Dimer

NCT03643068
View directory record Official record
Conditions
Healthy Adults
Interventions
KSP-QRH-E3-IRDye800 (Peptide 919288G), 0.6 mg, KSP-QRH-E3-IRDye800 (Peptide 919288G), 1.8 mg
Drug
Lead sponsor
University of Michigan
Other
Eligibility
25 Years to 100 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 6, 2018 · Synced Nov 1, 2026, 5:00 PM EST
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Flovent Discus vs QVAR vs Pulmicort Flexhaler on Short Term Growth

NCT01520688
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone, Budesonide, Beclomethasone, Fluticasone, Beclomethasone, Budesonide, Budesonide, Fluticasone, Beclomethasone, Budesonide, Beclomethasone, Fluticasone, Beclomethasone, Fluticasone, Budesonide, Beclomethasone, Budesonide, Fluticasone
Drug
Lead sponsor
West Penn Allegheny Health System
Other
Eligibility
6 Years to 11 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
2
States / cities
Green Tree, Pennsylvania • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 18, 2020 · Synced Nov 1, 2026, 5:00 PM EST
Completed Phase 2 Interventional Results available

PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network Study

NCT04129931
View directory record Official record
Conditions
Asthma
Interventions
MCT, Clazakizumab, Broncho-Vaxom, Imatinib Mesylate, Cavosonstat, Placebo
Drug · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
12 Years and older
Enrollment
950 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
29
States / cities
Scottsdale, Arizona • Tucson, Arizona • Sacramento, California + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Nov 1, 2026, 5:00 PM EST
Recruiting Phase 2 Interventional

Beginning to Assess an Appropriate CONtrol for Oral Food Challenges in Alpha-Gal Syndrome (CoFAR-13) - BeACON4AG

NCT07611435
View directory record Official record
Conditions
Alpha-Gal Syndrome, Allergy
Interventions
DBFC with 150g of Alpha-gal Knock Out (KO) pork, DBFC with 150g of Wild Type (WT) pork
Diagnostic Test
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years to 50 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
4
States / cities
Little Rock, Arkansas • Chapel Hill, North Carolina • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Nov 1, 2026, 5:00 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Food Effect on Drug Availability, Pharmacokinetic (PK) Properties, Safety and Tolerability of Two Different Dose Combination Therapy of Saxagliptin/Dapagliflozin/Metformin Extended-release (XR) Against Individual Component Co-administration.

NCT03169959
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
2.5 mg Saxagliptin tablet, 5 mg dapagliflozin / 1000 mg metformin XR tablet, Triple FCDP - 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR, 5 mg saxagliptin, 10 mg dapagliflozin / 1000 mg metformin XR tablet, Triple FCDP - 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 14, 2017 · Synced Nov 1, 2026, 5:00 PM EST
Terminated Not applicable Interventional Accepts healthy volunteers

A Precision Rehabilitation Approach to Counteract Age-Related Cognitive Declines

NCT03696082
View directory record Official record
Conditions
Cognition Disorders, Brain Pathology, Physical Disability, Physical Activity, Aging
Interventions
Aerobic Activity, Resistance Training, Yoga, Health Education
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
65 Years to 80 Years
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 22, 2023 · Synced Nov 1, 2026, 5:00 PM EST
Recruiting No phase listed Observational

Social Relationships and Accelerated Aging in Hematopoietic Cell Transplant Survivors

NCT04892823
View directory record Official record
Conditions
Hematopoietic and Lymphoid Cell Neoplasm
Interventions
Biospecimen Collection, Electronic Health Record Review, Questionnaire Administration
Procedure · Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Nov 1, 2026, 5:00 PM EST
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Mobile Parkinson Observatory for Worldwide, Evidence-based Research (mPower)

NCT02696603
View directory record Official record
Conditions
Parkinson Disease, Neurodegenerative Diseases, Movement Disorders, Central Nervous System Diseases, Brain Diseases, Basal Ganglia Diseases, Parkinsonian Disorders
Interventions
Participant self-assessment surveys, Phonation, Gait and balance, Memory, Dexterity, Participant open-response writing, Parkinson mPower mobile application
Behavioral · Other
Lead sponsor
Sage Bionetworks
Other
Eligibility
18 Years and older
Enrollment
20,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2025
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 11, 2025 · Synced Nov 1, 2026, 5:00 PM EST
Completed Phase 1 Interventional

A Study to Examine the Effects of Esomeprazole on the Pharmacokinetics of Orally Administered Lapatinib in Subjects With Metastatic ErbB2 Positive Breast Cancer

NCT00849329
View directory record Official record
Conditions
Neoplasms, Breast
Interventions
lapatinib, lapatinib plus esomeprazole
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Nov 14, 2017 · Synced Nov 1, 2026, 5:00 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Fixed Dose Combination of Macitentan/Tadalafil (10 mg/20 mg) Compared to the Reference Free Combination of Macitentan and Tadalafil in Healthy Adult Participants

NCT05236231
View directory record Official record
Conditions
Healthy
Interventions
Macitentan 10 mg, Tadalafil 20 mg, Macitentan 10 mg/Tadalafil 20mg FDC
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Nov 1, 2026, 5:00 PM EST
Completed Not applicable Interventional

Developmental and Augmented Intervention for Facilitating Expressive Language

NCT01013545
View directory record Official record
Conditions
Joint Engagement + Enhanced Milieu Training, Joint Engagement + Enhanced Milieu Training+Augmentative Communication (AAC)
Interventions
JAE Intervention
Behavioral
Lead sponsor
Autism Speaks
Other
Eligibility
5 Years to 8 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
3
States / cities
Los Angeles, California • Baltimore, Maryland • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 11, 2024 · Synced Nov 1, 2026, 5:00 PM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Modulation of Cognitive Control Signals in Prefrontal Cortex by Rhythmic Transcranial Magnetic Stimulation

NCT03828734
View directory record Official record
Conditions
Executive Function
Interventions
Theta TMS, Alpha TMS, Arrhythmic TMS
Device
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 35 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 19, 2020 · Synced Nov 1, 2026, 5:00 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Placebo and Moxifloxacin Controlled Cardiac Conduction Study of GSK2140944 in Healthy Volunteers

NCT02257398
View directory record Official record
Conditions
Infections, Respiratory Tract
Interventions
GSK2140944, GSK2140944 placebo, Moxifloxacin, Moxifloxacin placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 13, 2017 · Synced Nov 1, 2026, 5:00 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Diazepam After Intranasal and Intravenous Administration to Healthy Volunteers

NCT01364558
View directory record Official record
Conditions
Epilepsy
Interventions
Diazepam
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 1, 2019 · Synced Nov 1, 2026, 5:00 PM EST
Recruiting No phase listed Observational Accepts healthy volunteers

Heart Transplantation - Renewal

NCT05521399
View directory record Official record
Conditions
Transplant, Heart, Magnetic Resonance Imaging
Interventions
MRI Sequencing, MRI Testing (pediatric), MRI Testing
Diagnostic Test
Lead sponsor
Northwestern University
Other
Eligibility
Not listed
Enrollment
247 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2030
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Nov 1, 2026, 5:00 PM EST
Terminated Phase 2 Interventional

Treatment of Ragweed-Allergic Asthma With an Immunostimulatory Drug

NCT00318747
View directory record Official record
Conditions
Asthma, Allergy, Allergic Rhinitis, Rhinitis, Allergic, Seasonal
Interventions
Amb a 1-immunostimulatory oligodeoxyribonucleotide conjugate (AIC)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
4
States / cities
Baltimore, Maryland • Cincinnati, Ohio • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2013 · Synced Nov 1, 2026, 5:00 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Investigating Interactions Between BMS-986322 and Rosuvastatin, Metformin and Methotrexate in Healthy Participants

NCT05615012
View directory record Official record
Conditions
Healthy Participants
Interventions
BMS-986322, Rosuvastatin, Metformin, Glucose, Methotrexate, Leucovorin
Drug · Dietary Supplement
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 60 Years
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 27, 2024 · Synced Nov 1, 2026, 5:00 PM EST
Completed No phase listed Observational

DatScan With Prototype Collimator

NCT02455219
View directory record Official record
Conditions
Parkinson Disease
Interventions
Prototype UHRSZ (UltraHigh Resolution Smart Zoom) Collimator
Device
Lead sponsor
University of Minnesota
Other
Eligibility
50 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 2, 2018 · Synced Nov 1, 2026, 5:00 PM EST
Recruiting No phase listed Observational

ART-Pro: Clinical Trial Evaluating Biparametric MRI and Advanced, Quantitative Diffusion MRI for Detection of Prostate Cancer

NCT06579417
View directory record Official record
Conditions
Prostate Cancer
Interventions
RSI MRI
Diagnostic Test
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older · Male only
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
4
States / cities
San Diego, California • San Francisco, California • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2024 · Synced Nov 1, 2026, 5:00 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release With Respect to Metformin XR Tablet Coadministered With Canagliflozin in Healthy Fed and Fasted Participants

NCT02865668
View directory record Official record
Conditions
Healthy
Interventions
Canagliflozin and Metformin Extended Release (XR) Fixed Dose Combination [FDC], Canagliflozin, Metformin Extended Release (XR)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Nov 1, 2026, 5:00 PM EST
Completed Phase 1 Interventional

To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients

NCT00258050
View directory record Official record
Conditions
Neoplasms, Breast
Interventions
Midazolam, Lapatinib
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
2
States / cities
Lebanon, New Hampshire • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 6, 2017 · Synced Nov 1, 2026, 5:00 PM EST